©2024 Stanford Medicine
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
Not Recruiting
Trial ID: NCT02182986
Purpose
Solid organ transplantation is an important therapeutic option for children with a variety of
end stage diseases. However, the same immunosuppressive medications that are required to
prevent the child's immune system from attacking and rejecting the transplanted organ can
predispose these individuals to developing a very serious cancer that is linked to
Epstein-Barr virus (EBV).
Official Title
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children (CTOTC-06)
Stanford Investigator(s)
Carlos O. Esquivel, M.D., Ph.D.,FACS
Arnold and Barbara Silverman Professor in Pediatric Transplantation and Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Gastroenterology, Hepatology and Nutrition)
Eligibility
Inclusion Criteria:
- Subject and/or parent or legal guardian must be able to understand and provide
informed consent/assent;
- Candidate for or recipient of: heart, liver, heart with liver, small intestine, liver
with small intestine, or kidney; and
- Subject enrolled within 3 years of transplant.
Exclusion Criteria:
- Previous diagnosis of PTLD;
- Transplant recipients of lung alone, or in combination with an eligible organ type;
- Pancreas transplantation with the exception of 'en bloc' transplant in combined liver
and small intestine multivisceral transplantation;
- Any combination other than listed in inclusion criteria;
- History of any previous solid organ, stem cell, or bone marrow transplantation;
- Inability or unwillingness of the legal guardian and/or the subject to comply with the
study protocol.
Intervention(s):
procedure: transplant
drug: Immunosuppressive Drugs
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Sheri Krams, PhD
650-498-6246